Amantadine and memantine: a comprehensive review for acquired brain injury

References

• Ossolaa B, Schendzielorza N, Chenb S-H, Birdc GS, Tuominena RK, Männistöa PT, Hong JS. Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GNDF in astroglia. Neuropharmacology. 2011;61:574–82.
   PubMed Web of Science ®Google Scholar
• Aiyer R, Mehta N, Gungor S, Gulati A. A systematic review of NMDA receptor antagonists for treatment of neuropathic pain in clinical practice.Clin J Pain. 2017;34:1. doi:10.1097/AJP.0000000000000547.
   Web of Science ®Google Scholar
• Watkins J. Pharmacology of excitatory amino acid transmitters. Adv Biochem Psychopharmacol. 1981;29:205–12.
   PubMedGoogle Scholar
• Schüler T, Mesic I, Madry C, Bartholomäus I, Laube B.Formation of NR1/NR2 and NR1/NR3 heterodimers constitutes the initial step in n-methyl-d-aspartate receptor assembly.J Biol Chem. 2008;283:37–46. doi:10.1074/jbc.M703539200.
   PubMed Web of Science ®Google Scholar
• DT, Chapter Jane DE 12. Pharmacology of NMDA receptors. In: Biology of the NMDA Receptor, (ed.) Antonius M Van Dongen. 2009. Boca Raton, FL: CRC Press/Taylor & Francis
   Google Scholar
• Kalia LV, Kalia SK, Salter MW.NMDA receptors in clinical neurology: excitatory times ahead.Lancet Neurol. 2008;7:742–55. doi:10.1016/S1474-4422(08)70165-0.NMDA.
   PubMed Web of Science ®Google Scholar
• Li D, Yuan H, Ortiz-Gonzalez XR, Marsh ED, Tian L, McCormick EM, Kosobucki GJ, Chen W, Schulien AJ, Chiavacci R, Tankovic A. GRIN2D recurrent de novo dominant mutation causes a severe epileptic encephalopathy treatable with NMDA receptor channel blockers. Am J Hum Genet. 2016;99:802–16.
   PubMed Web of Science ®Google Scholar
• Munakata M, Kato R, Yokoyama H, Haginoya K, Tanaka Y, Kayaba J, Kato T, Takayanagi R, Endo H, Hasegawa R., et al. Combined therapy with hypothermia and anticytokine agents in influenza A encephalopathy. Brain Dev. 2000;22:373–77.
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Weller M, Schoppmeyer K, Riederer P. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl. 1994;43:91–104.
   PubMedGoogle Scholar
• Kraus MF, Smith GS, Butters M, Donnell AJ, Dixon E, Yilong C, Marion D. Effects of the dopaminergic agent and NMDA receptor antagonist amantadine on cognitive function, cerebral glucose metabolism and D2 receptor availability in chronic traumatic brain injury: a study using positron emission tomography (PET). Brain Injury. 2005;19:471–79.
   PubMed Web of Science ®Google Scholar
• Kim YW, Shin J-C, An Y.Changes in cerebral glucose metabolism in patients with posttraumatic cognitive impairment after memantine therapy: a preliminary study.Ann Nucl Med. 2010;24:363–69. doi:10.1007/s12149-010-0360-3.
   PubMed Web of Science ®Google Scholar
• Schnakers C, Hustinx R, Vandewalle G, Majerus S, Moonen G, Boly M, Vanhaudenhuyse A, Laureys S. Measuring the effect of amantadine in chronic anoxic minimally conscious state. J Neurol Neurosurg Psychiatry. 2008;79:224–25.
   PubMed Web of Science ®Google Scholar
• Sun M, Kong L, Wang X, Lu X, Gao Q, Geller AI.Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson’s disease.Brain Res. 2005;1052:119–29. doi:10.1111/j.1743-6109.2008.01122.x.Endothelial.
   PubMed Web of Science ®Google Scholar
• Wang Z, He X, Fan X.Postnatal administration of memantine rescues TNF-α-induced decreased hippocampal precursor proliferation.Neurosci Lett. 2018;662:173–80. doi:10.1016/j.neulet.2017.10.022.
   PubMed Web of Science ®Google Scholar
• Patrick PD, Buck ML, Conaway MR, Blackman JA.The use of dopamine enhancing medications with children in low response states following brain injury.Brain Inj. 2003;17:497–506. doi:10.1080/0269905031000070279.
   PubMed Web of Science ®Google Scholar
• Quack G, Hesselink M, Danysz W, Spanage R.Microdialysis studies with amantadine and memantine on pharmacokinetics and effects on dopamine turnover.J Neural Transm. 1995;46:97–105. doi:10.1016/S0723-2020(11)80108-6.
   Web of Science ®Google Scholar
• Sekizawa K, Yanai M, Yamaya M, Arai H, Sasaki H.Letters to the editor.Lancet. 1999;353:2157. doi:10.1016/S0140-6736(05)75593-8.
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Wada H, Sekizawa K, Arai H, Sasaki H.Amantadine and pneumonia.Lancet. 1999;353:1999. doi:10.1016/S0140-6736(98)05805-X.
   Web of Science ®Google Scholar
• Burgunder JM, Guttman M, Perlman S, Goodman N, van Kammen DP, Goodman LV. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington’s disease. PLoS Curr. 2011. doi:10.1371/currents.RRN1260.
   PubMedGoogle Scholar
• Nourbakhsh B, Revirajan N, Waubant E.Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): study design for a pragmatic, randomized, double-blind, crossover clinical trial.Contemp Clin Trials. 2018;64:67–76. doi:10.1016/j.cct.2017.11.005.
   PubMed Web of Science ®Google Scholar
• Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C, Movement Disorder Society Evidence‐Based Medicine Committee. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018 Aug;33(8):1248-1266.
   Web of Science ®Google Scholar
• Ashton AK, Hamer R, Rosen RC. Serotonin reuptake inhibitor-induced sexual dysfunction and its treatment: a large-scale retrospective study of 596 psychaitric outpatients.J Sex Marital Ther. 1997;23:165–75. doi:10.1080/00926239708403922.
   PubMed Web of Science ®Google Scholar
• Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, Eifert B, Long D, Katz DI, Cho S, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012;366:819–26.
   PubMed Web of Science ®Google Scholar
• Raupp-Barcaro IF, Vital MA, Galduróz JC, Andreatini R. Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials. Rev Bras Psiquiatr. 2018. doi:10.1590/1516-4446-2017-2393.
   PubMed Web of Science ®Google Scholar
• Stryjer R, Budnik D, Ebert T, Green T, Polak L, Weizman S, Spivak B. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs – an open-label study. Clin Neuropharmacol. 2014;37:79–81.
   PubMed Web of Science ®Google Scholar
• Wilcox SK, Garry A, Johnson MJ.Novel use of amantadine: to treat hiccups.J Pain Symptom Manage. 2009;38:460–65. doi:10.1016/j.jpainsymman.2008.10.008.
   PubMed Web of Science ®Google Scholar
• Clerici F, Vanacore N, Elia A, Spila-alegiani S, Pomati S, Da Cas R, Raschetti R, Mariani C. Memantine in moderately-severe-to-severe alzheimer ’ s disease a postmarketing surveillance study. Drugs Aging. 2009;26:321–32.
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Rigaud AS, Stöffler A, Möbius HJ, Forette F.Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).Stroke. 2002;33:1834–39. doi:10.1161/01.STR.0000020094.08790.49.
   PubMed Web of Science ®Google Scholar
• Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, Jarvik JG, Miller EN, Singer EJ, Ellis RJ, et al.Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study.Aids. 2007;21:1877–86. doi:10.1097/QAD.0b013e32813384e8\r00002030-200709120-00007 [ pii].
   PubMed Web of Science ®Google Scholar
• McLean R, Proudlock F, Thomas S, Degg C, Gottlob I.Congenital nystagmus: randomized, controlled, double-masked trial of memantine/gabapentin.Ann Neurol. 2007;61:130–38. doi:10.1002/ana.21065.
   PubMed Web of Science ®Google Scholar
• Shery T, Proudlock FA, Sarvananthan N, McLean RJ, Gottlob I.The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study.Br J Ophthalmol. 2006;90:839–43. doi:10.1136/bjo.2005.086322.
   PubMed Web of Science ®Google Scholar
• Thurtell MJ, Joshi AC, Leone AC, Tomsak RL, Kosmorsky GS, Stahl JS, Leigh RJ. Cross-over trial of gabapentin and memantine as treatment for acquired nystagmus. Ann Neurol. 2010;67:676–80.
   PubMed Web of Science ®Google Scholar
• Levac D, Colquhoun H, O’Brien KK.Scoping studies: advancing the methodology.Implement Science. 2010;5:1–9. doi:10.1186/1748-5908-5-69.
   PubMed Web of Science ®Google Scholar
• Colquhoun HL, Levac D, O’Brien KK, Straus S, Tricco AC, Perrier L, Kastner M, Moher D. Scoping reviews: time for clarity in definition, methods, and reporting. J Clin Epidemiol. 2014;67:1291–94.
   PubMed Web of Science ®Google Scholar
• Iwahashi J, Tsuji K, Ishibashi T, Kajiwara J, Imamura Y, Mori R, Hara K, Kashiwagi T, Ohtsu Y, Hamada N, et al. Isolation of amantadine-resistant influenza A viruses (H3N2) from patients following administration of amantadine in Japan. J Clin Microbiol. 2001;39:1652–53.
   PubMed Web of Science ®Google Scholar
• Sugaya N, Miura M.MiuraM99 influenzaA encephalopathy.Case.pdf. Pediatr Infect Dis J. 1999;18:734. doi:10.1097/00006454-199908000-00019.
   PubMed Web of Science ®Google Scholar
• Sugaya N.Influenza-associated encephalopathy in Japan: pathogenesis and treatment.Pediatr Int. 2000;42:215–18. doi:10.1046/j.1442-200x.2000.01200.x.
   PubMed Web of Science ®Google Scholar
• Sugaya N, Miura M.Amantadine therapy for influenza type A-associated encephalopathy.Pediatr Infect Dis J. 1999;18:734. doi:10.1097/00006454-199908000-00019.
   PubMed Web of Science ®Google Scholar
• Akçıl EF, Dilmen ÖK, Vehid H, Tunalı Y.Can amantadine ameliorate neurocognitive functions after subarachnoid haemorrhage? A preliminary study.Turk Anesteziyoloji Ve Reanimasyon Dern Derg. 2018;46:100–07. doi:10.5152/TJAR.2018.20280.
   Google Scholar
• Kafi H, Salamzadeh J, Beladimoghadam N, Sistanizad M, Kouchek M. Study of the neuroprotective effects of memantine in patients with mild to moderate ischemic stroke. Iran J Pharm Res. 2014;13:591–98.
   PubMed Web of Science ®Google Scholar
• Reynolds JC, Rittenberger JC, Callaway CW.Methylphenidate and amantadine to stimulate reawakening in comatose patients resuscitated from cardiac arrest.Resuscitation. 2013;84:818–24. doi:10.1016/j.resuscitation.2012.11.014.
   PubMed Web of Science ®Google Scholar
• Beers S, Skold A, Dixon C, Adelson P.Neurobehavioral effects of amantadine after pediatric traumatic brain injury: a preliminary report.J Head Trauma Rehabil. 2005;20:450–63. doi:10.1097/00001199-200509000-00006.
   PubMed Web of Science ®Google Scholar
• Kraus MF, Maki PM. Effect of amantadine hydrochloride on symptoms of frontal lobe dysfunction in brain injury: case studies and review. J Neuropsychiatry Clin Neurosci. 1997;9:222–30.
   PubMed Web of Science ®Google Scholar
• Mokhtari M, Nayeb-Aghaei H, Kouchek M, Miri MM, Goharani R, Amoozandeh A, Akhavan Salamat S, Sistanizad M. Effect of memantine on serum levels of neuron-specific enolase and on the glasgow coma scale in patients with moderate traumatic brain injury. J Clin Pharmacol. 2018;58:42–47.
   PubMed Web of Science ®Google Scholar
• Zafonte RD, Watanabe T, Mann NR.Amantadine: a potential treatment for the minimally conscious state.Brain Inj. 1998;12:617–21. doi:10.1080/026990598122386.
   PubMed Web of Science ®Google Scholar
• Arciniegas DB, Frey KL, Anderson CA, Brousseau KM, Harris SN.Amantadine for neurobehavioural deficits following delayed post-hypoxic encephalopathy.Brain Inj. 2004;18:1309–18. doi:10.1080/02699050410001720130.
   PubMed Web of Science ®Google Scholar
• Shahar E, Keidan I, Brand N, Frand M, Barzilay Z.Uncommon neurologic complications of burns in infants: a parkinsonian extrapyramidal disorder and massive cerebral infarction.J Burn Care Rehabil. 1991;12:54–57. doi:10.1097/00004630-199101000-00014.
   PubMedGoogle Scholar
• Kraus M, Maki P.The combined use of amantadine and l-dopa/carbidopa in the treatment of chronic brain injury.Brain Inj. 1997;11:455–60. doi:10.1080/026990597123430.
   PubMed Web of Science ®Google Scholar
• Giacino JT, Katz DI, Schiff ND, Whyte J, Ashman EJ, Ashwal S, Barbano R, Hammond FM, Laureys S, Ling, Geoffrey SF, et al. Practice guideline update recommendations summary: disorders of consciousness. Neurology. 2018;91:450–60.
   PubMed Web of Science ®Google Scholar
• Zorowitz RD, Smout RJ, Gassaway JA, Horn SD.Neurostimulant medication usage during stroke rehabilitation: the post-stroke rehabilitation outcomes project (PSROP).Top Stroke Rehabil. 2005;12:28–36. doi:10.1310/2403-B0CY-1UDN-4B6D.
   PubMedGoogle Scholar
• Nickels J, Schneider W, Dombovy M, Wong T.Clinical use of amantadine in brain injury rehabilitation.Brain Inj. 1994;8:709–18. doi:10.3109/02699059409151025.
   PubMed Web of Science ®Google Scholar
• Weinshilboum BR, Axel J.Serum dopamine-beta-hydroxylase activity.Circ Res. 1971;28:307–15. doi:10.1161/01.RES.28.3.307.
   PubMed Web of Science ®Google Scholar
• Edby K, Larsson J, Eek M, von Wendt L, Östergård B.Amantadine treatment of a patient with anoxic brain injury.Child’s Nerv Syst. 1995;11:607–09. doi:10.1007/BF00301001.
   PubMed Web of Science ®Google Scholar
• Shiller AD, Burke DT, Kim HJ, Calvanio R, Dechman KG, Santini C.Treatment with amantadine potentiated motor learning in a patient with traumatic brain injury of 15 years’ duration.Brain Inj. 1999;13:715–21. doi:10.1080/026990599121269.
   PubMed Web of Science ®Google Scholar
• Jang SH, Kwon HG. Recovery of an injured dentato-rubro-thalamic tract in a patient with traumatic brain injury. Neurol Asia. 2018;23:85–88.
   Web of Science ®Google Scholar
• Jang SH, Kim SH, Seo JP.Recovery of an injured corticofugal tract from the supplementary motor area in a patient with traumatic brain injury: a case report.Medicine (Baltimore). 2018;97:e9063. doi:10.1097/MD.0000000000009063.
   PubMed Web of Science ®Google Scholar
• Cohen JA, Hunter SF, Brown TR, Gudesblatt M, Thrower BW, Llorens L, Souza-Prien CJ, Ruby AE, Chernoff DN, Patni R. Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: a randomized, placebo-controlled, phase 2 trial.Mult Scler J. 2018;1–9. doi:10.1177/1352458518754716.
   Web of Science ®Google Scholar
• Baezner H, Oster M, Henning O, Cohen S, Hennerici MG, Ossola B, Schendzielorz N, Chen S-H, Bird GS, Tuominen RK.Amantadine increases gait steadiness in frontal gait disorder due to subcortical vascular encephalopathy: a double-blind randomized placebo-controlled trial based on quantitative gait analysis.Cerebrovasc Dis. 2001;11:235–44. doi:10.1159/000047645.
   PubMed Web of Science ®Google Scholar
• Kim YE, Yun JY, Yang HJ, Kim HJ, Gu N, Yoon SH, Cho JY, Jeon BS. Intravenous amantadine for freezing of gait resistant to dopaminergic therapy: a randomized, double-blind, placebo-controlled, cross-over clinical trial. PLoS One. 2012;7:1–6.
   Web of Science ®Google Scholar
• James W.Lecture III: the reality of the unseen.Var Relig Exp. 1999;27:51–54. doi:10.1111/j.1467-8705.1985.tb00797.x.
   Web of Science ®Google Scholar
• PVS TM-STF on. Medical aspects of the persistent vegetative state. NEJM. 1994;330:1499–508. doi:10.1056/NEJM199405263302107.
   PubMed Web of Science ®Google Scholar
• Giacino JT, Ashwal S, Childs N, Cranford R, Jennett B, Katz D, Kelly JP, Rosenberg JH, Whyte J, Zafonte RD, et al. The minimally conscious state definition and diagnostic criteria. Neurology. 2002;58:349–53.
   PubMed Web of Science ®Google Scholar
• Hirschberg R, Giacino JT.The vegetative and minimally conscious states: diagnosis, prognosis and treatment.Neurol Clin. 2011;29:773–86. doi:10.1016/j.ncl.2011.07.009.
   PubMed Web of Science ®Google Scholar
• Patrick PD, Blackman JA, Mabry JL, Buck ML, Gurka MJ, Conaway MR.Dopamine agonist therapy in low-response children following traumatic brain injury.J Child Neurol. 2005;21:879–85. doi:10.2310/7010.2006.00203.
   Web of Science ®Google Scholar
• Green LB, Hornyak JE, Hurvitz EA.Amantadine in pediatric patients with traumatic brain injury.Am J Phys Med Rehabil. 2004;83:893–97. doi:10.1097/01.PHM.0000143400.15346.C8.
   PubMed Web of Science ®Google Scholar
• Giacino JT, Trott CT.rehabilitative management of patients with disorders of consciousness grand rounds.J Head Trauma Rehabil. 2004;19:254–65. doi:10.1097/00001199-200405000-00006.
   PubMed Web of Science ®Google Scholar
• Wu TS, Garmel GM.Improved neurological function after amantadine treatment in two patients with brain injury.J Emerg Med. 2005;28:289–92. doi:10.1016/j.jemermed.2004.11.016.
   PubMed Web of Science ®Google Scholar
• Pan J, Rhee M.Poster 331 effectiveness of amantadine in anoxic brain injury: a case report.Pm&R. 2016;8:S268–9. doi:10.1016/j.pmrj.2016.07.501.
   Google Scholar
• Ghalaenovi H, Fattahi A, Koohpayehzadeh J, Khodadost M, Fatahi N, Taheri M, Azimi A, Rohani S, Rahatlou H. The effects of amantadine on traumatic brain injury outcome: a double-blind, randomized, controlled, clinical trial. Brain Inj. 2018;32:1–6.
   PubMed Web of Science ®Google Scholar
• Hughes S, Colantonio A, Santaguida PL, Paton T.Amantadine to enhance readiness for rehabilitation following severe traumatic brain injury.Brain Inj. 2005;19:1197–206. doi:10.1080/02699050500309296.
   PubMed Web of Science ®Google Scholar
• McMahon MA, Vargus-Adams JN, Michaud LJ, Bean J.Effects of amantadine in children with impaired consciousness caused by acquired brain injury: a pilot study.Am J Phys Med Rehabil. 2009;88:525–32. doi:10.1097/PHM.0b013e3181a5ade3.
   PubMed Web of Science ®Google Scholar
• Bobele GB, Bale J.Subacute encephalopathy in a 5-year-old boy.Semin Pediatr Neurol. 1999;6:168–72. doi:10.1016/S1071-9091(99)80008-4.
   PubMedGoogle Scholar
• Al-Adawi S, Hoaglin H, Vesali F, Dorvlo ASS, Burke DT.Effect of amantadine on the sleep-wake cycle of an inpatient with brain injury.Brain Inj. 2009;23:559–65. doi:10.1080/02699050902970745.
   PubMed Web of Science ®Google Scholar
• Raffaele R, Nicoletti G, Vecchio I, Ruggieri M, Malaguarnera M, Rampello L, Brunetto MB, Nicoletti F. Use of amantadine in the treatment of the neurobehavioral sequelae after brain injury in elderly patients.Arch Gerontol Geriatr. 2002;Suppl. 8:309–12.
   Google Scholar
• Lombard LA, Zafonte RD.Agitation after traumatic brain injury.Am J Phys Med Rehabil. 2005;84:797–812. doi:10.1097/01.phm.0000179438.22235.08.
   PubMed Web of Science ®Google Scholar
• Gualtieri T, Chandler M, Coons TB, Brown LT.Amantadine: a new clinical profile for traumatic brain injury.Clin Neuropharmacol. 1989;12:258–70. doi:10.1097/00002826-198908000-00003.
   PubMed Web of Science ®Google Scholar
• McLeod GF, Beck B, VandenBerg A, Stocking N. Under arrest the use of amantadine for treatment-refractory mood lability and aggression in a patient with traumatic brain injury. J Clin Psychopharmacol. 2015;35:2014–16.
   Web of Science ®Google Scholar
• Kazui H, Mori E, Hashimoto M, Hirono N.Phobia after bilateral thalamic hemorrhage [1].Cerebrovasc Dis. 2001;12:283–84. doi:10.1159/000047719.
   PubMed Web of Science ®Google Scholar
• Hammond FM, Malec JF, Zafonte RD, Sherer M, Bogner J, Dikmen S, Whitney MP, Bell KR, Perkins SM, Moser EA, et al. Potential impact of amantadine on aggression in chronic traumatic brain injury. J Head Trauma Rehabil. 2017;32:308–18.
   PubMed Web of Science ®Google Scholar
• Hammond FM, Bickett A, Norton J, Pershad R.Effectiveness of amantadine hydrochloride in the reduction of chronic traumatic brain injury irritability and aggression.J Head Trauma Rehabil. 2014;29:391–99. doi:10.1097/01.HTR.0000438116.56228.de.
   PubMed Web of Science ®Google Scholar
• Hammond FM, Sherer M, Malec JF, Zafonte RD, Whitney M, Bell K, Dikmen S, Bogner J, Mysiw J, Pershad R, et al. Amantadine effect on perceptions of irritability after traumatic brain injury: results of the amantadine irritability multisite study. J Neurotrauma. 2015;32:1230–38.
   PubMed Web of Science ®Google Scholar
• Gramish JA, Kopp BJ, Patanwala AE.Effect of amantadine on agitation in critically ill patients with traumatic brain injury.Clin Neuropharmacol. 2017;40:212–16. doi:10.1097/WNF.0000000000000242.
   PubMed Web of Science ®Google Scholar
• Mann S, Fogel BS, Hawkins J, Duffy J, Krupp B. Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci. 1995;7:23–30.
   PubMed Web of Science ®Google Scholar
• Rao V, Handel S, Vaishnavi S, Keach S, Robbins B, Spiro J, Ward J, Berlin F. Psychiatric sequelae of traumatic brain injury: a case report. Am J Psychiatry. 2007;164:728–35.
   PubMed Web of Science ®Google Scholar
• Reekum Van R, Bayley M, Garner S, Burke I, Fawcett S, Hart A, Thompson W. N of 1 study: amantadine for the antimotivational syndrome in a patient with traumatic brain injury. Brain Inj. 1995;9:49–53.
   PubMed Web of Science ®Google Scholar
• McGrane IR, Loveland JG, Zaluski HJ.Adjunctive amantadine treatment for aggressive behavior in children: a series of eight cases.J Child Adolesc Psychopharmacol. 2016;26:935–38. doi:10.1089/cap.2016.0042.
   PubMed Web of Science ®Google Scholar
• Berthier ML, Green C, Lara JP, Higueras C, Barbancho MA, Davila G, Pulvermüller F. Memantine and constraint-induced aphasia therapy in chronic poststroke aphasia. Ann Neurol. 2009;65:577–85.
   PubMed Web of Science ®Google Scholar
• Yarns BC, Quinn DK.Telephone effect in akinetic mutism from traumatic brain injury.Psychosomatics. 2013;54:609–10. doi:10.1016/j.psym.2013.06.006.
   PubMed Web of Science ®Google Scholar
• Barrett AM, Levy CE, Gonzalez Rothi LJ.Pharmaceuticals for poststroke and brain injury rehabilitation.Am J Phys Med Rehabil. 2007;86:603–04. doi:10.1097/PHM.0b013e3181148ce0.
   PubMed Web of Science ®Google Scholar
• Barbancho MA, Berthier ML, Navas-Sánchez P, Dávila G, Green-Heredia C, García-Alberca JM, Ruiz-Cruces R, López-González MV, Dawid-Milner MS, Pulvermüller F, et al. Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: an ERP study. Brain Lang. 2015;145–146:1–10.
   PubMed Web of Science ®Google Scholar
• Yarns BC, Quinn DK.Telephone effect in akinetic mutism from traumatic brain injury.Psychosomatics. 2013;54:609–10. doi:10.1016/j.psym.2013.06.006.
   PubMed Web of Science ®Google Scholar
• Barrett AM, Eslinger PJ.Amantadine for adynamic speech: possible benefit for aphasia?Am J Phys Med Rehabil. 2007;86:605–12. doi:10.1097/PHM.0b013e31811473b3.
   PubMed Web of Science ®Google Scholar
• Mobius HJ, Stoffler A.New approaches to clinical trials in vascular dementia: memantine in small vessel disease.Cerebrovasc Dis. 2002;13:61–66. doi:10.1159/000049153.
   PubMed Web of Science ®Google Scholar
• Wilcock G, Mobius H, Soffler A.A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).Int Clin Psychopharmacol. 2002;17:297–305. doi:10.1097/00004850-200211000-00005.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Navia BA, Marra CM, Singer EJ, Chang L, Berger J, Ellis RJ, Kolson DL, Simpson D, Miller EN, et al. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials. 2010;11:59–67.
   PubMed Web of Science ®Google Scholar
• Meythaler JM, Brunner RC, Johnson A, Novack TA.Amantadine to improve neurorecovery in traumatic brain-injury-associated diffuse axonal injury: a pilot double-blind randomized trial.J Head Trauma Rehabil. 2002;17:300–13. doi:10.1097/00001199-200208000-00004.
   PubMed Web of Science ®Google Scholar
• Hammond F, Sherer M, Malec JF, Zafonte RD, Dikmen SP, Bogner JA, et al. Amantadine did not positively impact cognition in chronic traumatic brain injury: a multi-site, randomized, controlled trial. J Neurotrauma. 2018;8:1–8.
   Google Scholar
• Sood V, Azariah AF, O’Brien K, Byars J, DiTommaso C, Kothari S.Unconventional dosing of amantadine in a patient with traumatic brain injury: a case report.PM R. 2016;8:S235. doi:10.1080/02699052.2017.1312145.
   PubMedGoogle Scholar
• Schneider WN, Drew-Cates J, Wong TM, Dombovy ML.Cognitive and behavioural efficacy of amantadine in acute traumatic brain injury: an initial double-blind placebo-controlled study.Brain Inj. 1999;13:863–72. doi:10.1080/026990599121061.
   PubMed Web of Science ®Google Scholar
• Polich G, Iaccarino MA, Kaptchuk TJ, Morales-Quezada L, Zafonte R.Placebo effects in traumatic brain injury.J Neurotrauma. 2018;1212. doi:10.1089/neu.2017.5506.
   Web of Science ®Google Scholar
• Reddy CC, Collins M, Lovell M, Kontos AP.Efficacy of amantadine treatment on symptoms and neurocognitive performance among adolescents following sports-related concussion.J Head Trauma Rehabil. 2013;28:260–65. doi:10.1097/HTR.0b013e318257fbc6.
   PubMed Web of Science ®Google Scholar
• Giacino JT, Whyte J, Bagiella E, Kalmar K, Childs N, Khademi A, Eifert B, Long D, Katz DI, Cho S, et al. Placebo-controlled trial of amantadine for severe traumatic brain injury. N Engl J Med. 2012;366:819–26.
   PubMed Web of Science ®Google Scholar
• Hinkle JL., Amantadine hydrochloride, J Neurosci Nurs. 1991;23(2):80.
   Google Scholar
• Shaygannejad V, Janghorbani M, Ashtari F, Zakeri H.Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study.Neurol Res. 2012;34:854–58. doi:10.1179/1743132812Y.0000000081.
   PubMed Web of Science ®Google Scholar
• Lovera JF, Frohman E, Brown TR, Bandari D, Nguyen L, Yadav V, Stuve O, Karman J, Bogardus K, Heimburger G, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16:715–23.
   PubMed Web of Science ®Google Scholar
• Hartshorne NJ, Harruff RC, Logan BK.Unexpected amantadine intoxication in the death of a trauma patient.Am J Forensic Med Pathol. 1995;16:340–43. doi:10.1097/00000433-199512000-00009.
   PubMed Web of Science ®Google Scholar
• Nakai K, Takeda K, Kimura H, Miura S, Maeda A.Obstructive acute renal failure related to amantadine intoxication.Am J Emerg Med. 2009;27:7–9. doi:10.1016/j.ajem.2008.07.020.
   Google Scholar
• Perry MS, Bailey LJ, Kotecha AC, Malik SI, Hernandez AW.Amantadine for the treatment of refractory absence seizures in children.Pediatr Neurol. 2012;46:243–45. doi:10.1016/j.pediatrneurol.2012.02.004.
   PubMed Web of Science ®Google Scholar
• Wilson RB, Eliyan Y, Sankar R, Hussain SA.Amantadine: a new treatment for refractory electrical status epilepticus in sleep.Epilepsy Behav. 2018;84:74–78. doi:10.1016/j.yebeh.2018.04.018.
   PubMed Web of Science ®Google Scholar
• Schwab RS, England AC, Poskanzer DC, Young RR.Amantadine in the treatment of Parkinson’ s disease.Jama. 1969;208:1168–70. doi:10.1001/jama.1969.03160070046011.
   PubMed Web of Science ®Google Scholar
• Terzano MG, Montanari E, Calzetti S, Mancia D, Lechi A.The effect of amantadine on arousal and EEG patterns in Creutzfeldt-Jakob disease.Arch Neurol. 1983;40:555–59. doi:10.1001/archneur.1983.04050080055010.
   PubMedGoogle Scholar
• Nogaki H, Morimatsu M.Superficial punctate keratitis and corneal abrasion due to amantadine hydrochloride.J Neurol. 1993;240:388–89. doi:10.1179/sre.2006.38.300.499.
   PubMed Web of Science ®Google Scholar
• Fann WE, Lake CR.Amantadine versus trihexyphenidyl in the treatment of neuroleptic induced Parkinsonism.Am J Psychiatry. 1976;133:940–43. doi:10.1176/ajp.133.8.940.
   PubMed Web of Science ®Google Scholar
• Ito T, Shibata K, Watanabe A, Akabane J.Neuroleptic malignant syndrome following withdrawal of amantadine in a patient with influenza A encephalopathy.Eur J Pediatr. 2001;160:401. doi:10.1007/s004310100743.
   PubMed Web of Science ®Google Scholar
• Yung CY.Case vignettes of movement disorders.Brain Res Bull. 1983;11:191–94. doi:10.1016/0361-9230(83)90190-9.
   PubMed Web of Science ®Google Scholar
• Thornton SL, Clark RF.Encephalopathy from unintentional donepezil and memantine ingestion.Pediatr Emerg Care. 2014;30:649–50. doi:10.1097/PEC.0000000000000216.
   PubMed Web of Science ®Google Scholar
• Schoen B, Eickmeyer S.Acute hallucinosis related to amantadine use in the setting of traumatic brain injury: a case report.Pm R. 2016;8:S178. doi:10.1016/j.pmrj.2016.07.095.
   PubMedGoogle Scholar
• Karli DC, Burke DT, Kim HJ, Calvanio R, Fitzpatrick M, Temple D, Macneil M, Pesez K, Lepak P. Effects of dopaminergic combination therapy for frontal lobe dysfunction in traumatic brain injury rehabilitation. Brain Inj. 1999;13:63–68.
   PubMed Web of Science ®Google Scholar
• Whyte J.Treatments to enhance recovery from the vegetative and minimally conscious states: ethical issues surrounding efficacy studies.Am J Phys Med Rehabil. 2007;86:86–92. doi:10.1097/PHM.0b013e31802f0434.
   PubMed Web of Science ®Google Scholar
• Editor J. Parkinson’s disease and amantadine hydrochloride. JAMA. 1969;208:1180–81.
   Web of Science ®Google Scholar
• Whyte J, Nordenbo AM, Kalmar K, Merges B, Bagiella E, Chang H, Yablon S, Cho S, Hammond F, Khademi A, et al. Medical complications during inpatient rehabilitation among patients with traumatic disorders of consciousness. Arch Phys Med Rehabil. 2013;94:1877–83.
   PubMed Web of Science ®Google Scholar